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Abstract
Infection caused by Bordetella pertussis in young infants can lead to severe illness and 
death. Several countries with good pertussis vaccine coverage, above 90%, had outbreaks 
of this disease from 2010, including Brazil. One of the strategies to reduce the transmis-
sion of pertussis to young infants, especially below 6 months of age, is the introduction of 
Tdap vaccination in pregnant women between 27 and 36 weeks of gestation. Vaccination 
of pregnant women with Tdap is an emergency measure to reduce hospitalizations and 
deaths from pertussis in young infants, especially those younger than 3 months of age, 
which is the population group where the most frequent serious illness occurs. Passive 
immunity to pertussis in these newborns is temporary, lasting less than 6 months, and 
there is discussion in the literature of its interference with maternal immunity and immu-
nity of young infants to other vaccines. The acquired immunity to pertussis, both by 
natural disease and by vaccines, is temporary, and it is known that the immune response 
to the acellular vaccine is smaller and less durable than the whole-cell vaccine. New strat-
egies for pertussis control should be developed to better cope with this disease overall.
Keywords: pertussis, Bordetella pertussis, whole-cell pertussis vaccines, acellular 
pertussis vaccines, maternal pertussis vaccination, passive protection, infants, vaccine 
effectiveness, whooping cough
1. Introduction
Whopping cough is mentioned in medical literature since 1540, in the pre-vaccine era, 
when the incidence of the disease ranged from 100 to 200 cases per 100,000 people [1, 2]. 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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This same incidence is observed nowadays in many developing countries and also in 
some high-income countries among children under 1 year of age. The vaccine age begins 
in the 1940s with the whole-cell pertussis vaccines (wP vaccines) and in 1992 with acel-
lular pertussis vaccines (aP vaccines) in developed countries, with a marked decrease 
in the number of sick individuals as well as in the number of hospitalizations. Despite 
this, there has been an increase in the incidence and deaths due to pertussis in infants 
fewer than 6 months of age between 1980 and 2010 in the USA, in Europe, and in many 
other countries [1–5]. Whooping cough is a highly infectious disease caused by Bordetella 
pertussis and, more rarely, by Bordetella parapertussis, B. bronchiseptica, or B. holmesii. It 
is the most ill-controlled vaccine-preventable bacterial disease in countries with high 
vaccination coverage, in which disease peaks occur every 3–5 years. Although routine 
childhood vaccination has produced a substantial reduction in the number of cases, it 
continues to cause high morbidity and mortality in children in countries across the globe 
[6–8]. In developed countries with pertussis vaccination coverage above 90–95%, such as 
the USA, the UK, several European countries, and Australia, pertussis has manifested in 
children under 6 months of age when they have not yet completed their primary series 
and in adolescents and adults who lost their immunity induced by the vaccine (the last 
booster is given at the age of 5 years). Young infants present atypical and potentially seri-
ous conditions, with about 50% of the cases leading to hospitalizations and often even 
to death, while adolescents and adults also present atypical but mild symptomatology, 
and as a result, the individual is often mistakenly diagnosed with other infections of the 
upper respiratory tract [2, 3, 9, 10]. The causes of the decreasing immunity to pertussis 
are varied: from the primary vaccine failure due to bacterial adaptations to the failure 
of the vaccine to eliminate the bacteria from the carriers’ organism and thereby prevent 
transmission to the dropping of protective antibodies. The duration of protection of the 
acellular vaccines is approximately 3 years, with 85% efficacy, and the risk of contracting 
the disease increases by 1.33 times each year after the last dose of the vaccine. Therefore, 
the vaccine protects against the disease, but not against bacterial colonization and its con-
sequent transmission. Loss of vaccine-derived protection over time and increased circula-
tion of B. pertussis lead to increased susceptibility of adolescents and adults. As a result, 
whooping cough is often reported as a cause of persistent cough in adolescents and adults 
[6, 11–14]. The variation in the notification of the age group affected by pertussis can 
be explained in part by a growing recognition of the less typical manifestations of the 
disease in adolescents and adults and by severe cases in young infants. It can also be 
explained by the development of more sensitive laboratory tests and by a more sensitive 
and extended healthcare surveillance to cover all life periods [15–17]. Outbreaks in areas 
of high vaccination coverage demand a review of vaccination strategies. It is necessary to 
take into account adolescent and adult transmitters, as well as health professionals and 
pregnant women. In order to better assess changes in epidemiology over time and to opti-
mize disease control, it is important to improve whooping cough surveillance, from clini-
cal recognition of the disease to laboratory diagnosis [18]. In 2013, according to the WHO 
estimates, pertussis caused about 63,000 deaths in children under 5 years of age, although 
there is considerable uncertainty about these estimates in view of the scarcity of reliable 
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surveillance data, especially in developing countries [16, 19]. In 2014, pertussis global 
vaccination coverage was estimated at 86%, considering adherence to the vaccine primary 
series of three doses. A change in age distribution of the disease for older children and 
certain age groups (adolescents and young adults) has been reported in recent years in 
some high-income countries, in particular where aP vaccines have replaced wP vaccines 
in primary series and booster doses [15, 16]. High vaccination coverage needs to be main-
tained in order to ensure protection of newborns and young infants, the two groups most 
likely to show the most severe symptoms and who have not yet started or did not com-
plete their primary series of vaccines. The recent shortage of pertussis vaccine in Europe 
and elsewhere represents a considerable challenge for maintaining such coverage [18]. 
It is estimated that the incidence of whooping cough is actually 6–9 times higher than 
the reported cases, which in 2016, according to the WHO, were 139,535 cases. The unfa-
miliarity with the disease and its incorrect diagnosis seem to be particularly common 
among adolescents and adults, due to its atypical clinical presentation. Persistent cough 
is often the only sign of the disease, and this signal can be attributed to many other condi-
tions and is generally not correlated to whooping cough; so, diagnostic is not performed. 
On the other hand, the search for specific antibodies in respiratory secretions of patients 
with chronic cough usually comes as negative. Only serology will identify the cases, and, 
in turn, serology may not be able to differentiate current active cases from recent cases. 
The actual incidence of pertussis remains unknown, because data collection varies greatly 
between countries, which affect the interpretation of trends. There are also variations in 
the diagnostic methods for laboratory confirmation, in the definition of a case of pertussis 
and the clinical diagnosis itself [18, 20, 21]. In addition to all the difficulties of data collec-
tion, there is still the issue of high contagiousness of the disease, even among vaccinated 
individuals. A study carried out on vaccinated children, aged 1–5 years, in a preschool 
class, who had contact with a pertussis case, observed attack rates approaching 50%. This 
shows the importance of diagnostic investigations even in vaccinated children. The clini-
cal condition will also highly depend on the history of each child, which emphasizes the 
seriousness of the matter [22].
2. Whooping cough: current situation
There is no consensus as to why the number of pertussis cases has increased in countries 
with high vaccination coverage. The reasons range from improvements in diagnosis, ear-
lier diagnosis, and more accurate surveillance. These changes have led to an increase in the 
number of reported cases, but there is also evidence of increased circulation of the bacteria 
in the population. There are several other explanations for increased epidemics: changes in 
circulating pertussis virulence, vaccine failure against new bacteria, vaccine failure to block 
transmission of infection, decreased adherence to vaccination, rapid loss of immunity in 
adolescents and adults due to the vaccine or due to the disease itself over time, making the 
vaccinated individuals susceptible, and also the increase of susceptible individuals in the 
population [10, 17, 23–25].
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2.1. Loss of immunity
Neither vaccination nor disease induces long-term protection against pertussis. Loss of pro-
tection occurs from 4 to 12 years after the last dose of vaccine and from 7 to 20 years after an 
episode of disease. The duration of protection of the whole-cell vaccine corresponds to that of 
the natural infection [3, 25].
The protection evoked by the vaccine tends to get lost over time. Predicted time of the drop of 
antibody protective levels after vaccination to pre-vaccine levels varies according to different 
antigens: 15.3 years for pertactin, 11 years for fimbria types 2 and 3, 5 years for pertussis toxin 
(PT), and 9.5 years for filamentous hemagglutinin. Adolescent vaccination has a good cost-
benefit, since it leads to a significant reduction in costs with the disease, but yet not all devel-
oped countries provide the booster dose for individuals aged between 10 and 17 years. There 
is evidence that immunization of adolescents also does not provide long-term protection, 
which may lead to the risk of adults and elderly people being more affected by infection. This 
raises the issue that adults should also receive booster doses, since adolescents and adults 
only have protection for a few years, and should receive booster doses every 10 years [20].
The antibodies to pertactin are correlated to the protection of the disease, but nowadays there 
is an increase of non-pertactin producing B. pertussis strains. In developed countries that use 
the acellular vaccine (which has pertactin as one of its components), loss of immunity may 
occur, as well as failure to prevent colonization by pertussis. However, other components of 
the vaccine (pertussis toxin, filamentous hemagglutinin, or fimbriae) also seem to prevent 
symptomatic pertussis [26].
2.2. Pertussis genetic changes
Genetic changes in B. pertussis may be one of the factors that have contributed to the recent 
reappearance of whooping cough. In the USA, isolated cases of Bordetella pertussis without 
pertactin have increased from 14% in 2010 to 85% in 2012. The effectiveness of the acellular 
vaccine appears to remain the same, but surveillance for the adaptations and mutations of the 
bacteria must be enhanced, as new genotypes have been reported [26, 27].
2.3. Current situation around the world
In the USA, notable increases in pertussis disease occurred in 2004 (25,827 cases, 27 deaths), in 
2010 (27,550 cases, 27 deaths), and, more recently, in 2012, when more than 41,000 cases and 
18 deaths have been reported, the largest number of cases in the USA since 1959. In addition, 
the epidemiological characteristics of whooping cough have changed in recent years with an 
increased load of disease among fully vaccinated children and adolescents [28].
In 2012 when whooping cough was epidemic in the USA, there was an incidence of 103 cases 
per 100,000 inhabitants in Vermont. These evidences suggest a resurgence of pertussis in the 
USA [3, 26].
According to the WHO SAGE pertussis working group report in April 2014 [3], the data from 
the USA suggest a decrease in immunity after aP vaccine replaced wP, but no impact was 
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observed on overall infant mortality. It also indicates the limited duration of the protection 
for pertussis in adolescents, pointing to the need for booster vaccination in adolescents who 
received the aP vaccine compared to those who had at least one dose of wP. There was no 
resurgence of the disease in Canada, but the periodic cycle had a higher peak in 2012 than in 
the previous two cycles. An increase in reported cases was limited to certain regions and hap-
pened over short periods. In general, the situation in the country is very heterogeneous with 
multiple causes for increase in pertussis cases (low vaccine coverage, decreasing immunity, 
previous wP vaccine with low efficacy), but there is no evidence that aP has contributed to 
the most recent increase in cases. The data suggest that the immunity induced by aP vaccines 
decreases before the booster dose of adolescence. Therefore, it can be concluded that the tim-
ing of adolescent’s vaccination is important and that the age in which the third booster is 
commonly ministered (14–16 years old) may be too late.
In Brazil, a country that still uses wP vaccines, national vaccination coverage in infants under 
1 year of age with DTP3 (diphtheria-tetanus-pertussis) vaccine was high (>95%) between 
2001 and 2011. From 2006 to 2012, the number of municipalities with coverage above 95% 
decreased from 83 to 55%, resulting in a heterogeneous coverage throughout the country. 
The causes for the decline were mainly operational issues due to supply and social problems. 
In Brazil, the number of pertussis cases increased from 2001 to 2012, with a large increase in 
morbidity and mortality among infants under 1 year old. This increase was attributed in part 
to improvements in surveillance sensitivity. Between 2007 and 2012, 51% of reported cases 
of whooping cough in children under 6 months of age did not receive any dose of vaccine, 
37% received only one dose against whooping cough, and 12% received 2 or more doses. The 
majority of deaths, 342 (97%), occurred in children younger than 1 year of age. The increase 
in fatal cases among children under 6 months of age led the country to introduce the aP 
vaccine in pregnant women and also to recommend a cocooning strategy. The recurrence of 
the natural cycle, the drop in vaccination coverage, and the increase in laboratory tests may 
be responsible for the increase in the number of cases. There is no evidence of diminishing 
immunity, as cases are predominant in young infants not yet immunized, supported by the 
fact that the increase is not observed in older age groups, and the change in disease activity 
does not exceed what would normally be expected in epidemic cycles [3, 29].
In Chile, the quality of data was improved in 2012, since the laboratory methods were pre-
viously not ideal. The resurgence of whooping cough observed in 2011 and 2012 was pre-
ceded by a drop in vaccine coverage and thus may be partly linked to this fall [3]. In Cuba, 
the notification is based only on the clinical definition, without laboratory confirmation. The 
country’s data is therefore not comparable with data from other countries, thereby limiting 
its usefulness [3]. In Mexico, the data quality has serious limitations, and the sensitivity of 
the surveillance system is low. The increase in cases may be related to the low and hetero-
geneous vaccination coverage. The use of a more sensitive laboratory method (PCR) may 
explain the recent increase in cases, an idea supported by the dissociation of the total infant 
cases from whooping cough and infant mortality in 2012 [3]. In the European Union (EU), 
40,727 cases of whooping cough were notified in 29 countries in 2014. The reporting rate was 
9.1 cases per 100,000 inhabitants, higher than in 2013 but lower than in the epidemic year of 
2012 [18]. Germany reported 12,339 cases (15.3 cases per 100,000 inhabitants) in 2014. Rates 
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were highest among children under 1 year of age (51.6 cases per 100,000 individuals), fol-
lowed by 10–14 years (24.4 per 100,000) and 15–19 years (19.7 per 100,000). The German data 
is of good quality; therefore, the hypothesis of resurgence of the disease can be discarded. A 
low overall incidence and low numbers of hospitalizations are observed despite the years of 
recurrent outbreaks. The increase in incidence may be due to the greater number of serologi-
cal tests in adolescents [3, 18]. Spain has had a higher mortality rate and hospitalization for 
whooping cough in children under 3 months of age in 2010 (142.55/100,000) [30–32]. The situ-
ation in Denmark is stable, with an observed increase in cases occurring by natural recurrent 
cycles of the disease and by the use of serological diagnosis. Denmark is the only country 
with the exclusive use of monovalent aP vaccine: primary immunization begins at 3 months 
of age, followed by doses at 5 and 12 months. Since 2004, the total number of reported cases 
has remained relatively stable since the introduction of the aP vaccine, contrary to what has 
been reported by other countries that have used long-term aP vaccines [3, 5]. The observed 
epidemiology of Finland is explained by naturally occurring cycles. The situation is stable; 
no statistically significant change in trends is identified after 2003–2004. Since the aP vac-
cine was introduced in 2005, the time elapsed is still short to allow observation of possible 
resurgence of the disease due to the decrease in aP-related immunity. In France, there was no 
resurgence of the disease, with the aP vaccine being used in the past 10 years with a high cov-
erage. Available data suggest a recent increase in incidence in the age range between 5 and 10, 
which may reflect an increasing decrease in protection in cohorts exclusively vaccinated with 
aP. New strategies, such as adult reinforcement and cocooning, have not had a major impact, 
and their level of implementation remains low [3]. The incidence of pertussis in Belgium at 
all ages was estimated from 24.2 to 30.8 per 100,000 individuals in 2014. In a study with iden-
tification of B. pertussis with real-time PCR, the culture of these cases was positive in 30%. 
In this same study, 60% of the cases were positive in serology with anti-PT antibodies, two 
serology samples were required, and rare cases were positive for both methods, with which 
it was demonstrated that diagnosis may require both microbiological and immunological 
methods [3, 25, 33]. In Portugal, there was a significant increase in incidence in infants under 
1 year of age, suggesting a true resurgence of the disease, although the increased incidence 
may also be associated with the increased use of the PCR test. Pertussis infant mortality was 
very high in 2012, while mortality from the period 2000 to 2011 was similar to that of other 
countries. There is likely underreporting in the older age groups. The whole-cell vaccine was 
replaced by acellular vaccine in 2006. In Sweden there has been no resurgence of pertus-
sis to date, and there have been no major outbreaks since 2004. There has been a successive 
reduction in the overall incidence of whooping cough since the reintroduction of the vaccine 
against pertussis after a 17-year period without the vaccine [3]. In the UK, evidence suggests 
a resurgence of whooping cough. Although the incidence has declined in the last 20 years, 
there has been no interruption of the natural epidemic cycle, which happens every 3–4 years. 
A real increase over the natural cycle was observed in infants younger than 3 months of age 
in 2011 and 2012. An increase in reported cases, hospitalizations, and the number of deaths 
in young infants was observed. The actual resurgence of pertussis was recorded 7 years after 
the introduction of the aP vaccine, coinciding with the peak of the natural epidemic cycle [3]. 
In Eastern European countries, there have been several outbreaks, whose incidence varied 
from 0.01 to as high as 96 per 100,000 inhabitants. The highest index was found in Estonia 
[34]. The data available in Israel do not provide clear evidence of the resurgence of pertussis. 
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Possible explanations for the increase in child cases include greater awareness of whooping 
cough and the availability of better laboratory tests. Vaccination coverage is high in Israel, 
which has been using aP (ranging from 3 to 5 components) for the past 7 years [3]. Incidence 
data for children under 6 years of age in Japan were highest in 2000. The most recent data 
(2010) show an increase in cases of adults over 20 years. This increase was surprisingly not 
reflected in young infants, and only a small increase can be observed among older children. 
No data were obtained concerning hospitalizations and deaths related to whooping cough 
in Japan. There is no evidence of resurgence, although data are limited [35]. The quality of 
the data is good in Singapore, and there is no evidence of the resurgence of whooping cough 
[3]. The data does not allow drawing conclusions about the sudden increase in pertussis in 
2007 among those unimmunized or with incomplete immunization, which may be due to the 
introduction of PCR or whether it was a real increase with case duplication in 2007. Despite 
the two peaks in 2007 and 2011, the overall incidence was low. The recent rise in whooping 
cough began shortly after moving from wP to aP vaccine in 2006. Data quality is limited 
in Thailand, since cases are underreported and there is a low sensitivity of the surveillance 
system. There is no evidence of a resurgence of whooping cough: incidence remained low 
between 2009 and 2014. Thailand uses only wP vaccination [3, 36]. In Australia, there was a 
resurgence of whooping cough between 2008 and 2012 in children under 10 years of age, in 
particular at 2–4 and 7–9 age ranges. Pertussis is an important public health issue in Australia, 
with continuous increases observed over a long period of time. The increase was observed at 
first in adults, related to the availability of serological tests, and then in adolescents, which 
was related to a history of low coverage of vaccines. More recently, increase of pertussis was 
observed in younger children, consistent with declining immunity in the context of increased 
availability and use of tests. Withdrawal of the booster dose in early childhood (at 18 months 
of age) appears to have made an important contribution to the resurgence of the disease in 
children aged 2–4 years, with decreasing immunity after the last dose of acellular vaccine at 
6 months. The 18-month vaccine was reintroduced in 2015. As in the USA, Australia had large 
increases of the disease in children over 6 years of age [3, 37, 38].
There are few publications on pertussis in Africa, and most of them do not contain surveil-
lance data and epidemiological trends. In addition we have lack of laboratories capable of 
adequate diagnosis [39]. Based on the WHO data, the number of cases of pertussis in Africa 
decreased from 2000 to 2010, except in 2011, when an increase occurred [40]. The WHO in 
2016 reported 139,535 cases of pertussis in the world, and in Africa we had only 1425 reported 
cases [21]. Nigeria, on the other hand, had a peak in whooping cough activity in 2009, report-
ing the second largest number of cases worldwide, and the diagnosis was made primarily 
clinical as there are few laboratories for the research [40]. In some African countries, wP vac-
cine coverage is very low, as measured in Chad (22%), Equatorial Guinea (33%), Gabon (45%), 
Nigeria (47%), Liberia 49%), Ethiopia (51%), Central African Republic (54%), Guinea (59%), 
Cote d’Ivoire (62%), and Cameroon (68%) [40]. The WHO African Regional Office (AFRO) is 
working on reducing missed opportunities for vaccination in 20 priority countries represent-
ing 30% (5.9 million) of the unvaccinated or partially vaccinated global birth cohort [41].
Country-specific data provided no evidence of a widespread resurgence of whooping cough 
globally. The increase in the number of pertussis cases observed in recent years has been 
attributed to cyclical patterns in most countries, probably amplified by increased disease 
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awareness, increased global laboratory tests, and increased sensitivity of diagnostic methods, 
as well as by the use of PCR amplification. Recurrent natural cycles may be more visible in 
countries where surveillance is more sensitive and where disease control in recent years has 
generally been good.
Data from only five of these countries (Australia, Chile, Portugal, the USA, and the UK) sup-
ported the hypothesis of a real resurgence in pertussis-related morbidity in recent years com-
pared to previous periods of time. Only one country that used wP vaccine against pertussis, 
Chile, reported a resurgence. For the time being, the increase in cases can be attributed to a 
sustained decrease in vaccine coverage, to variable coverage at the district level, to changes 
in surveillance practices, as well as to problems with the specificity of diagnostic tests. The 
increase in infant cases was noteworthy and associated with increased disease mortality. 
However, since this was based on fluorescent antibody test data alone (which is known to 
have problems with specificity), more data will be needed for a better characterization of the 
problem [3, 39].
3. Vaccination and control strategies
There is a wide variety of vaccine calendars in the world. By 2015, 86% of children world-
wide (116.1 million) received three doses of diphtheria, tetanus, and pertussis (DTP) vaccines. 
However, to reach coverage of 95% or more, 13.5 million unvaccinated children should be 
vaccinated annually, and an additional 6 million children with incomplete vaccination should 
complete the timeline. Restricted access and missed opportunities for vaccination remain a 
challenge worldwide, as well as for middle- and upper-income countries [41].
3.1. Newborns
The increased incidence of whooping cough in countries with high vaccine coverage is alarm-
ing, with rates only previously seen in 1950. The protection of newborns is urgently needed, 
especially during the period between birth and the first dose of the vaccine [10].
Vaccination in newborns is not an option at the present time, both due to the immaturity 
of the immune system of the newborn and its weak response to the vaccine. Besides these 
factors, the vaccine against pertussis may also interfere with the newborn’s response to the 
hepatitis B vaccine. For the protection of the newborn, we currently can resort to three related 
strategies: cocooning, booster schedule, and vaccination of pregnant women [10, 42].
3.2. Children: primary vaccination and booster schedule
The WHO recommends three doses of vaccine in the primary series, the first dose being given 
at 6 weeks of age (at the latest at 8 weeks of age). The second dose should be given 4–8 weeks 
after the first one. The last dose should be given at 6 months of age or at any opportunity 
after. Delaying the third dose may reduce protection against severe illness in the first year of 
life. A booster dose is recommended after 1 year of age, preferably in the second year of life, 
6 months after the primary vaccination scheme. In countries that use aP vaccine, protection 
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diminishes before the age of 6 years old, whereas those who use wP offer a protection that 
lasts for 6 years or more. A second booster dose should be given from 4 to 6 years of age for 
both vaccines [16, 43].
National programs currently administering wP vaccination should continue to use wP vac-
cines for the primary vaccination series. National programs currently using the aP vaccine 
may continue to use this vaccine but should consider the need for additional booster doses 
and additional strategies, such as maternal immunization in case of pertussis resurgence. 
Only the aP vaccine can be administered in individuals from the age of 7 onward. Vaccination 
at this age must be based on cost-effectiveness mindset, since the priority is always to main-
tain high vaccination coverage in the first years of life [16].
3.3. Adolescents and adults: booster schedule
The acellular vaccine was introduced in 1992 in the American calendar, and in 1997 it was 
already part of the entire childhood calendar (2, 4, 6, and 15 months and 4–6 years). In 2006, 
a booster dose was introduced at 11–12 years old. Despite this, there was a large outbreak in 
2012 in children vaccinated with the acellular vaccine, probably due to the loss of immunity, 
lower immune response induced by the aP, increased awareness and notification, as well as 
improved diagnostic techniques, and possibly genetic alterations of the bacteria [26].
One of the reasons for the increase in pertussis is the loss of immunity induced by the vaccine 
or by infection among adolescents and adults. This leads to the discussion about the need for 
changes in the vaccine calendars of adolescents and adults. In countries with high vaccination 
coverage, there has also been an increase in pertussis cases in adolescents and adults in recent 
years, which is one of the causes of the onset of diseases in young infants, so a vaccine booster 
in adolescence and adulthood is recommended in order to reduce the spread of the disease 
among young infants [20].
The duration of immunity of the wP vaccine is 4–12 years, and the aP protection begins to 
diminish after 4–5 years. This led to the need of a booster dose in the adolescence (from 8 to 
11 years), because adolescents present low levels of antibodies, which increase later in life 
(from 12 to 15 years) due to natural infection [44].
Although a booster dose in adolescence has been shown to decrease the disease in adolescents, 
this is generally not recommended as a means of controlling disease in infants. Introduction 
of reinforcements in adolescents and/or in adults should only be done after evaluation of local 
epidemiology [16, 43]. Adult vaccination in most countries with high vaccination coverage 
is done with dT, and even when done with dTap, as in the USA, this occurs in only 14.2% of 
adults who have done so in the last 7 years [45].
One of the risk factors associated with pertussis in young infants is the presence of a house-
hold contact, usually parents, siblings, or caregivers, with a cough for 5 days or more [46].
3.4. Pregnant women: booster doses
One of the strategies to reduce the transmission of pertussis to young infants, especially less 
than 6 months of age, is the introduction of Tdap vaccination in pregnant women between 27 
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and 36 weeks of gestation in all pregnancies (not just the first one). Vaccination of the preg-
nant woman is most effective when administered 28 days or more before delivery, when a 
greater number of antibodies are transferred to the fetus. No adverse events were reported 
for the mother or the newborn with this measure, except for a small significant increase in 
chorioamnionitis seen by Kharbanda in 2014 [47–50]. The transplacental transfer of vaccine-
induced antibodies from the pregnant woman to the fetus before birth and through maternal 
breastfeeding after birth is the basis of the prenatal immunization [19]. If the mother is vac-
cinated with the aP vaccine during pregnancy, her maternal antibodies against pertussis will 
also be transferred to the newborn through breast milk [46].
In 2012, vaccination of pregnant women in the third trimester of pregnancy was instituted 
by the American Centers for Disease Control and Prevention (CDC), regardless of their vac-
cination status, due to the loss of immunity a few months after booster vaccination. Several 
studies have attested the safety of dTap use in pregnant women [51, 52]. These studies showed 
that women vaccinated before pregnancy had less than 50% detectable antibodies against per-
tussis during gestation, which led to the adoption of the measure of vaccinating the woman at 
each gestation, regardless of her previous vaccination status [10, 53]. Vaccination in pregnant 
women between 27 and 36 weeks is more effective for the prevention of pertussis in young 
infants than vaccination in the second trimester of pregnancy. On the other hand, it is known 
that the vaccine given at the beginning of this period of 27–31 weeks is more effective in 
reducing pertussis in young infants. Efforts should be made for adequate vaccination sched-
ule during prenatal consultations. Vaccination of 27–36 weeks is 85% more effective than Tdap 
postpartum vaccination [12, 51].
In the UK, vaccination was introduced in 2012 for pregnant woman between 28 and 32 weeks. 
In 2016, the country began recommending vaccination between 16 and 32 weeks, in order to 
improve the chance of vaccination to protect preterm infants, as well as to improve the level 
of maternal antibodies at birth. Later, vaccination during pregnancy protects the mother from 
developing the disease, giving some degree of protection to the newborn. Some studies have 
shown that women who were vaccinated after 32 weeks of pregnancy did not have the best 
level of passive protection for the newborn. In Belgium, the orientation for pregnant women 
is from 24 to 32 weeks of gestation [19, 25, 54, 55].
The timing of pregnant women vaccination is still controversial, with recent studies recom-
mending it in the second trimester of pregnancy, while previous studies advocated for the 
third trimester [10, 52].
The recommendation of vaccination in pregnant women has expanded to several countries, 
such as Argentina, Belgium, Brazil, Colombia, El Salvador, Mexico, New Zealand, Australia, 
Switzerland, Ireland, the Czech Republic, Israel, Spain, and Greece [19].
It is known that the transfer of maternal antibodies to the newborn can interfere with the 
response of young infants to their own vaccination [56, 57], a phenomenon called blunting. 
This phenomenon depends on the type of vaccine antibody: the PT antibody increases after 
primary immunization, but the FHA antibody decreases in infants born from mothers vacci-
nated during pregnancy [19, 58, 59]. A study showed that the level of antibodies in the newborn 
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and infants of mothers vaccinated for pertussis was adequate and protective, although their 
levels were slightly lower after the first three doses of the vaccine, and there was no difference 
in antibody levels after the first booster in the second year of life [10]. Monitoring the immunity 
of children vaccinated or not should be done regardless of age, in order to understand the long-
term impact and the real significance of these immunological findings [19].
Prenatal vaccination induces protection against pertussis by producing high levels of anti-
bodies, which are transferred to the fetus. This strategy will protect newborns when they are 
vulnerable to the disease, which happens mainly in the period before they complete their 
primary vaccination schedule with all three doses of the vaccine [19].
Vaccination in pregnant women is the most cost-effective strategy for disease prevention 
in young infants and unvaccinated newborns. It is more effective to vaccinate the pregnant 
mother than to vaccinate those interacting with the baby. The vaccine should be given in the 
second or third trimester of pregnancy, at least 15 days before delivery. This strategy should 
be adopted in countries with high or increasing morbidity and mortality of young infants due 
to pertussis [16, 60].
3.5. Caregivers: cocooning strategy
The cocooning strategy consists of vaccinating the whole family and intimate contacts of the 
newborn, in addition to vaccination of the pregnant woman. It is important to remember that 
the vaccine takes 2 weeks to raise the antibodies to protective levels; therefore, the newborn 
is exposed to the transmission of the pertussis during this critical period [20]. Vaccination of 
household members is effectively provided as it is performed in a timely manner [16]. All 
caregivers of young infants (who feed, dress, and bathe them regularly) should also be con-
sidered for vaccination [46]. It is necessary to achieve adherence by all of those in contact with 
the newborn or young infant, in order to obtain the effectiveness of the cocooning strategy. 
It is important to note that the mother accepts this initiative better than the father of the child 
and other relatives tend to accept it even more rarely [20].
In an American study of 115 young infants with severe pertussis, 72% had previously had 
contact with adults or children over 11 years of age who showed acute cough for 5 days or 
more, referred to in the last month. This contact was often with the mother. The fact that 
infants received a dose of aP did not protect them from the disease [46]. The route of contami-
nation was usually through a member of the family [6].
It has been observed that infants and young infants with older siblings are also at increased 
risk for pertussis. Each older sibling of the young infant increases the chance of having pertus-
sis 1.5 times more, speaking in favor of the hypothesis that the source of contamination is the 
older sibling [12].
The American CDC recommends vaccination with a dose of Tdap for every adult and adoles-
cent who have contact or who live with infants younger than 12 months of age [50]. Chile also 
adopted this strategy in 2011 with a significant impact: there was an 84% reduction in infant 
mortality when comparing cocooning strategy with no action taken [3].
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Cocooning doses may reduce the serious morbidity of the infant, but timing is crucial, and 
the overall impact and cost-effectiveness may vary between countries and situations. The 
advantages of cocooning are better acceptance of vaccination in the postpartum period than 
during pregnancy, accessibility to the whole family, and the opportunity for health educa-
tion. Disadvantages are the slow response to produce immunity to protect the newborn and 
logistical and economic issues. In addition, the challenges to implementing cocooning strat-
egies include parental refusal, political hardship, logistical issues, and cultural issues. The 
cost–benefit ratio of cocooning is lower than maternal immunization, since it requires only 
one dose, whereas the cocooning strategy requires at least two doses for both parents [3, 61].
Vaccination of pregnant women is likely to be the most cost-effective additional strategy to 
prevent pertussis disease in young infants and appears to be more effective and favorable 
than the cocooning strategy.
3.6. Healthcare professionals: booster schedule
In countries that have implemented pertussis vaccination for adults, vaccination of healthcare 
workers should be given priority, but there is no evidence that this decreases the acquisition 
or transmission of the disease but otherwise avoids nosocomial disease transmitted to new-
borns and young infants. Health professionals in contact with pregnant women, parturients, 
newborns, and young infants should also be prioritized. New studies are needed to assess the 
real impact of this measure [16, 44, 62].
4. Conclusions
Health education programs are needed to improve adherence to the pertussis immunization 
programs. Scientific divulgation of the disease and its prevention strategies are fundamental. 
Vaccination, especially for pregnant women and young infants, must also be publicized, as 
well as the discussion for incorporation of the vaccine against pertussis into the vaccination 
programs for adolescents, adults, and the elderly.
Vaccination for pertussis has had a major impact in reducing the overall burden of the dis-
ease, with a general reduction in its incidence and, in particular, a reduction in infant mortal-
ity. Nevertheless, the cyclic and recurrent patterns of whooping cough are still observed in 
countries with high vaccine coverage. New vaccination schemes against pertussis have been 
developed to reduce the risk of serious illness in young infants and young children. It is neces-
sary that all children worldwide, including HIV-positive individuals, be immunized against 
pertussis, and every country should seek to reach the entire population with anti-pertussis 
vaccination and also maintain high coverage (≥90%) at all levels (national and district).
Both the wP and aP vaccines are effective in reducing infant mortality, highlighting the impor-
tance of timely vaccination and the need to maintain high coverage, as current data point to 
a decrease in aP-related immunity. One future challenge may be the improvement of new 
vaccines considering all these factors, as well as the importance of the production of vaccines 
against parapertussis, which seems to be more frequent than originally imagined.
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Determining the true incidence of pertussis in each country is vital in order for health authori-
ties to devise the best vaccine strategies to control the disease and its consequences.
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